Dallas, Texas 11/04/2013 (Financialstrend) – Valeant Pharmaceuticals Intl Inc (NYSE:VRX) reported $1.54B in total revenue for the Q3, which was a 74% rise from the same quarter in 2012.Products sales amounted to a total of $1.5B, which was, up from $852.7M in the same quarter in 2012. Developed markets revenue amounted to $1.14B, a 77% rise from the Q3 of 2012. This was primarily attributed to the Bausch & Lomb acquisition.
Emerging markets revenue amounted to a total of $399 million, a 68% rise from the same quarter in 2012. This also was a result of the Bausch & Lomb acquisition. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) reported a net-loss of $973M for the Q3 , a loss of $2.92/share, due to one-time impairment-charges, settlement of the contract dispute & restructuring, integration & other charges which mainly stemmed from the Bausch & Lomb acquisition.
R&D costs totaled $49M which was a rise from $19M in comparison to the 2012 Q3.
For the 9-month period that ended 30 Sept, revenue totaled $3.7B which was up from $2.6B in the same quarter of 2012. Product-sales totaled $3.6B, up from $2.3B in the previous year.
In Friday’s trading, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rose by 5.18%. The opening price of the shares was $106.00, which climbed to an intraday high of $111.42 and dipped to a close of $111.20. Approximately 2.53 million shares were traded on Friday while an average volume of 1.30 million shares were traded over a 30 day period. The 52-week low of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares is $52.50 and its 52-week high is $115.39. The company has a market capitalization of $37.01 billion.
About the company
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was previously Biovail Corporation. It is a multi-national, specialty-pharmaceutical company that is involved in developing, manufacturing and marketing a variety of pharmaceutical products.